325eP Prehabilitation in lung cancer patients undergoing radiotherapy/chemoradiotherapy: A systematic review

Background: Neoadjuvant chemoimmunotherapy has improved outcomes for patients with resectable non-small cell lung cancer (NSCLC), enhancing survival and reducing recurrence.It is emerging as a new standard of care, although the optimal treatment combination and predictive biomarkers remain under investigation.This study aimed to evaluate and compare the efficacy of neoadjuvant treatment strategies in resectable NSCLC based on immune checkpoint inhibitor (ICI) therapy. Methods:Patients with clini